Welcome to our dedicated page for Skye Bioscience news (Ticker: SKYE), a resource for investors and traders seeking the latest updates and insights on Skye Bioscience stock.
Skye Bioscience, Inc. (Nasdaq: SKYE) is a cutting-edge, clinical-stage biopharmaceutical company based in San Diego, California. Focused on the development of innovative therapies, Skye leverages the endocannabinoid system to address diseases characterized by metabolic, inflammatory, and fibrotic processes.
The company's prominent clinical candidates include nimacimab and SBI-100 Ophthalmic Emulsion (SBI-100 OE). Nimacimab is a groundbreaking humanized monoclonal antibody that functions as a negative allosteric modulator of the cannabinoid 1 receptor (CB1). By targeting CB1 in peripheral tissues, nimacimab aims to treat diseases like obesity, chronic kidney disease, and metabolic dysfunction-associated steatohepatitis (MASH) without the central nervous system (CNS) side effects that plagued earlier CB1 inhibitors. Currently, Skye is gearing up for a Phase 2 clinical trial of nimacimab in patients with obesity and chronic kidney disease, expected to begin in mid-2024.
Meanwhile, SBI-100 OE is under investigation for its potential to lower intraocular pressure in patients suffering from glaucoma and ocular hypertension. Although the Phase 2a trial did not meet its primary endpoint for reducing intraocular pressure, the drug demonstrated a favorable safety profile, paving the way for further research and development.
Recent news highlights Skye's strategic focus and financial stability. As of June 2024, the company announced the discontinuation of clinical development for SBI-100 OE, allowing Skye to redirect resources fully towards its metabolic program, extending its operational runway into 2027. Backed by leading life science venture investors, including Perceptive Advisors and 5AM Ventures, Skye successfully raised $90.25 million through two private placements in the first quarter of 2024, ensuring robust financial resources to support its ambitious clinical development plans.
For more information, please visit the company's website at www.skyebioscience.com.
Skye Bioscience (OTCQB: SKYE) announced the completion of SBI-100 Ophthalmic Emulsion production for its Phase 1 clinical trial, which focuses on treating glaucoma. The final product is expected to be clinically available in October, pending quality testing results. Clinical site initiation will occur in mid-October, followed by patient dosing starting in November. SBI-100 OE aims to effectively lower intraocular pressure (IOP) using a novel synthetic cannabinoid formulation, potentially offering a new treatment class for glaucoma, a leading cause of irreversible blindness.
Skye Bioscience, Inc. (OTCQB: SKYE) announced the filing of its definitive proxy statement ahead of a special meeting on September 30, 2022. This meeting will address a proposed business combination with Emerald Health Therapeutics, Inc. Stockholders as of August 29, 2022, will receive voting materials via mail or email. CEO Punit Dhillon expressed gratitude for Emerald's support and emphasized the importance of stockholder voting to secure valuable resources for their business plan. The definitive proxy statement is available for viewing online.
Skye Bioscience (OTCQB: SKYE) announces that 87.07% of Emerald Health Therapeutics shareholders approved the proposed merger plan. The next step involves Skye seeking shareholder approval in an upcoming meeting. Regulatory approval for Skye's Phase 1 clinical study has been granted, with enrollment expected to complete by early 2023. The company plans to submit its Investigational New Drug application to the FDA by year-end 2022 for a Phase II study on SBI-100 targeting glaucoma, a condition affecting over 70 million people worldwide.
FAQ
What is the current stock price of Skye Bioscience (SKYE)?
What is the market cap of Skye Bioscience (SKYE)?
What does Skye Bioscience, Inc. specialize in?
What are the main clinical candidates for Skye Bioscience?
What recent financial developments has Skye Bioscience announced?
What is the status of Skye Bioscience's SBI-100 Ophthalmic Emulsion?
When is the Phase 2 clinical trial for nimacimab expected to start?
What diseases does nimacimab target?
Who are Skye Bioscience's key investors?
What is Skye Bioscience's strategy for clinical development?
How can I contact Skye Bioscience for more information?
What is the focus of Skye Bioscience's current research and development efforts?
